Cala Health Receives FDA Clearance for Cala ONE Wrist Device

Burlingame, CA – April 26, 2018 – Cala Health announced today that the US Food and Drug Administration (FDA)
has granted a De Novo request for Cala ONE, an individualized prescription neuromodulation therapy for
transient relief of hand tremors in adults with essential tremor (ET). Cala ONE is the first-ever non-invasive,
targeted nerve stimulator for the treatment of ET to receive FDA marketing authorization. Evidence on Cala ONE
was presented as part of a late-breaking emerging science session at the American Academy of Neurology 70th
Annual Meeting in Los Angeles, CA on April 25, 2018 by Rajesh Pahwa, MD, University of Kansas Medical Center.